Yes, top line data only. The benefit (as measured by CGI-I) of NTI164 is the same as FDA approved DAYBUE (-0.3) which is good.
The secondary endpoint data will be instructive - if the side effects of the NTI drug are better than DAYBUE then that may be a selling point.
Yes, top line data only. The benefit (as measured by CGI-I) of...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $62.07M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 247860 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 150000 | 1 |
View Market Depth
| Last trade - 09.45am 23/09/2024 (20 minute delay) ? |
| NTI (ASX) Chart |
Day chart unavailable